Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
July 10, 2024 07:30 ET
|
Longeveron
Longeveron® Announces U.S. FDA Grants Lomecel-B(TM) Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease